In addition, on January 11, 2021, bluebird announced certain planned future changes in the composition of its board of directors and management in connection with, and contingent upon successful completion of its announced
intent to separate its core severe genetic disease and its oncology businesses into two independent, publicly-traded companies (bluebird and Oncology Newco, respectively). Effective upon the separation, which is
expected to be completed by the end of 2021: Effective upon the separation, which is expected to be completed by the end of 2021: Nick Leschly would become chief executive officer of Oncology Newco and executive chair of the board of directors of bluebird. Daniel Lynch would become chair of the board of directors of Oncology Newco, and step down from his position as chair of the board of directors of bluebird.
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
BLUEBIRD BIO, INC. 
